TY - JOUR T1 - Philadelphia-negative myeloproliferative neoplasms as disorders marked by cytokine modulation JO - Hematology, Transfusion and Cell Therapy T2 - AU - Cacemiro,Maira da Costa AU - Cominal,Juçara Gastaldi AU - Tognon,Raquel AU - Nunes,Natalia de Souza AU - Simões,Belinda Pinto AU - Figueiredo-Pontes,Lorena Lôbo de AU - Catto,Luiz Fernando Bazzo AU - Traina,Fabíola AU - Souto,Elizabeth Xisto AU - Zambuzi,Fabiana Albani AU - Frantz,Fabiani Gai AU - Castro,Fabíola Attié de SN - 25311379 M3 - 10.1016/j.htct.2017.12.003 DO - 10.1016/j.htct.2017.12.003 UR - http://www.htct.com.br/en-philadelphia-negative-myeloproliferative-neoplasms-as-disorders-articulo-S253113791830018X AB - BackgroundCytokines are key immune mediators in physiological and disease processes, whose increased levels have been associated with the physiopathology of hematopoietic malignancies, such as myeloproliferative neoplasms. MethodsThis study examined the plasma cytokine profiles of patients with essential thrombocythemia, primary myelofibrosis, polycythemia vera and of healthy subjects, and analyzed correlations with JAK2 V617F status and clinical-hematological parameters. ResultsThe proinflammatory cytokine levels were increased in myeloproliferative neoplasm patients, and the presence of the JAK2 V617F mutation was associated with high IP-10 levels in primary myelofibrosis patients. ConclusionsEssential thrombocythemia, primary myelofibrosis, and polycythemia vera patients exhibited different patterns of cytokine production, as revealed by cytokine network correlations. Together, these findings suggest that augmented cytokine levels are associated with the physiopathology of myeloproliferative neoplasms. ER -